TARRYTOWN, N.Y., March 25, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2026 financial and operating results on Wednesday, April 29, 2026, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the ’Investors and Media’ page of Regeneron’s website at http ...

Key Takeaways Regeneron shares surged 31.5% in six months, driven by pipeline progress and strong earnings.Dupixent growth and label expansions boost revenues, while Eylea faces decline and rising biosimilar pressure.Oncology and new drugs like Libtayo and Lynozyfic support diversification beyond core franchises.The going has been strong for Regeneron Pharmaceuticals (REGN) over the past six months. Shares of this biotech giant have surged 31.5% in this time frame, outpacing the industry’s growth of 13.5%. ...

Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained disease remission through Week 36 compared with placebo BP is a chronic, relapsing skin disease with underlying type 2 inflammation characterized by intense itch alongside painful blisters and other lesions BP is the seventh approved indication for Dupixent in Japan TARRYTOWN, N.Y. and PARIS, March 24, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ ...

Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid Approval in moderate-to-severe patients was based on pivotal study results showing over four times more Dupixent patients experienced sustained disease remission through Week 36 compared with placeboBP is a chronic, relapsing skin disease with underlying type 2 inflammation characterized by intense itch alongside painful blisters and other lesionsBP is the seventh approved indication for ...

Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid Approval in moderate-to-severe patients was based on pivotal study results showing over four times more Dupixent patients experienced sustained disease remission through Week 36 compared with placeboBP is a chronic, relapsing skin disease with underlying type 2 inflammation characterized by intense itch alongside painful blisters and other lesionsBP is the seventh approved indication for ...

Core Thesis - Regeneron Pharmaceuticals, Inc. (REGN) is viewed positively due to its strong innovation capabilities and the success of its flagship drug, Dupixent, which has expanded its indications and is expected to generate significant revenue [3][4][5] Financial Metrics - As of March 11th, REGN's share price was $774.66, with trailing and forward P/E ratios of 18.68 and 18.05, respectively [1] Product Success - Dupixent is recognized as a blockbuster drug, initially approved for atopic dermatitis and now also used for asthma and other inflammatory diseases, showcasing its efficacy and expanding patient base [3][4] Revenue Generation - The anticipated revenue from Dupixent is expected to be substantial and recurring, allowing Regeneron to reinvest in research and development, thus creating a self-sustaining cycle of innovation [4][5] Pipeline and Innovation - Regeneron has developed a broad pipeline that includes oncology, cardiovascular medicine, and rare diseases, supported by proprietary platforms and scientific expertise, which enhances its competitive position in the biotech sector [4][5] Long-term Growth Potential - The company's strategy leverages the success of Dupixent to fund future innovations, positioning Regeneron for sustained growth and reinforcing its status as a major player in the global biopharmaceutical market [5]

Core Viewpoint - Regeneron Pharmaceuticals is positioned for significant growth, with the potential to double investors' returns in the coming years due to its promising pipeline and strong financial performance [2][12]. Company Overview - Regeneron Pharmaceuticals is a leading biotech company known for developing treatments across various disease categories, including eye diseases, cancer, and rare diseases [5]. - The company has a market capitalization of $82 billion and has delivered a 106% gain over the past decade [2]. Financial Performance - In 2025, Regeneron's revenue rose 1% to $14.3 billion, while earnings per share increased by 8% to $41.48 [9]. - The company's lead therapy, Dupixent, generated $17.8 billion in revenue in 2025, with additional significant products including Eylea and Libtayo [5][9]. Product Pipeline - Regeneron has 26 candidates in late-stage trials, with expectations for at least four FDA approvals in the current year [3][8]. - The company is also investigating olatorepatide, a GLP-1 weight loss and diabetes candidate, which could significantly boost revenue if approved [10][11]. Market Potential - Analysts predict that olatorepatide could generate $14.8 billion in annual revenues by 2028, surpassing the company's total revenue from the previous year [11]. - The weight-loss drug sector is projected to grow from $4.2 billion in 2025 to $23.6 billion by 2030, indicating substantial market opportunities for Regeneron [12].

Group 1 - The management team of Regeneron, including Marion McCourt and Ryan Crowe, is present to discuss the company's business prospects for the year [1] - Regeneron emphasizes its commercial momentum and the strength of its diverse pipeline, along with a disciplined approach to capital allocation [2] - The company plans to provide an overview of its current strategies and future outlook during the presentation [2]

Regeneron Pharmaceuticals Conference Call Summary Company Overview - **Company**: Regeneron Pharmaceuticals (NasdaqGS:REGN) - **Date**: March 11, 2026 - **Key Speakers**: Marion McCourt (Executive Vice President of Commercial), Ryan Crowe (Senior Vice President of Investor Relations and Strategy) Core Industry Insights Commercial Performance - **EYLEA HD**: - Q4 sales reached **$506 million**, marking a **66% year-over-year growth** [11] - Label enhancements in November included weekly dosing and RVO indication [11] - **DUPIXENT**: - Q4 sales totaled **$4.9 billion**, a **32% increase** year-over-year [12] - Strong performance across all indications, with significant growth in asthma and new launches in COPD and CSU [13][14] - **Libtayo**: - Generated **$525 million** in Q4, a **13% year-over-year increase** [12] Market Dynamics - **DUPIXENT** remains the leading product in its category, with significant under-penetration in atopic dermatitis [13] - EYLEA is facing competition from biosimilars, leading to expected declines in its sales, although EYLEA HD is showing high single-digit growth [16][17] - The company anticipates additional biosimilar competition for EYLEA in the second half of the year [17] Pipeline Developments New Product Launches - **Lynozyfic**: Recently launched for later-line patients, showing positive uptake [14] - **Cemdisiran**: Expected approval for generalized myasthenia gravis (MG) by early next year, with a potential market size of **$5 billion** today, projected to reach **$10 billion** by 2030 [47] - **Geographic Atrophy (GA)**: Combination therapy with cemdisiran and pozelimab is in development, with interim analysis expected by the end of 2026 [55] Strategic Partnerships - The alliance with **Sanofi** has been crucial for the success of DUPIXENT, with **1.4 million patients** currently on the medication [26] - Discussions are ongoing regarding the potential extension of the alliance and leveraging both companies' pipelines for future growth [27][28] Financial Strategy - Regeneron emphasizes a disciplined approach to capital allocation and is open to M&A opportunities that align with its therapeutic focus [21][22] - The company is building out its commercial infrastructure to support new product launches and expand its therapeutic areas [22][40] Risks and Considerations - The company acknowledges the risks associated with forward-looking statements and the potential impact of biosimilar competition on EYLEA sales [3][4] - There is a focus on ensuring the safety and efficacy of new products in the market, particularly in the context of competitive pressures [36] Conclusion - Regeneron Pharmaceuticals is positioned for continued growth with a strong commercial performance in key products like DUPIXENT and EYLEA HD, while also expanding its pipeline with promising new therapies. The strategic alliance with Sanofi remains a cornerstone of its success, and the company is actively exploring opportunities for future growth through M&A and new product launches.

Company Overview - Regeneron Pharmaceuticals, Inc. is a well-established biotech company based in Tarrytown, NY, founded in 1988 and has experienced significant growth since reaching an inflection point in 2011 [1] Investment Philosophy - The company emphasizes the importance of patient investing through good and bad times, highlighting the joy of compounding and the value of dividend reinvesting as key to wealth creation [1] Investment Strategy - The investment approach combines steady accumulation of high-quality assets with high-risk/high-reward opportunities, underappreciated turnaround plays, and transformative technologies [1]